Streetbeat News

Analyst Ratings

VIRX

RBC Capital analyst Gregory Renza has maintained an Outperform rating on Viracta Therapeutics (NASDAQ:VIRX) but has reduced the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:33 pm

TSNDF

Following TerrAscend Corp.'s (OTC:TSNDF) strong Q3 earnings, analysts from Clarus Securities, Echelon Capital Markets, ATB Capital Markets, and Canaccord Genuity have raised their price targets and upgraded their ratings. Clarus Securities increased their target to $3.50 with a 'Buy' rating. Echelon Capital Markets upgraded to 'Speculative Buy' with a C$2.75 target. ATB Capital Markets gave an 'Outperform' rating with a C$4.00 target, and Canaccord Genuity raised their target to C$3.25, maintaining a 'Buy' rating.

Portfolio Pulse from Javier Hasse

November 10, 2023 | 7:30 pm

TDG

RBC Capital analyst Ken Herbert has reaffirmed an Outperform rating on TransDigm Group Incorporated (NYSE:TDG) and increased the price target from $975 to $1150, signaling confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:30 pm

VERX

BMO Capital Markets analyst Daniel Jester maintained a Market Perform rating on Vertex, Inc. (NASDAQ:VERX) but increased the price target from $24 to $28 after the company's Q3 earnings beat and raised guidance. Vertex's Q3 total revenues were up 14.9% year-over-year at $145 million. The stock experienced a significant move post-earnings, which was unexpected. Jester sees a balanced risk/reward for VERX in the near term and has adjusted FY23 and FY24 revenue estimates upwards, while slightly lowering the FY24 EPS estimate.

Portfolio Pulse from Nabaparna Bhattacharya

November 10, 2023 | 7:29 pm

TTD

RBC Capital analyst Matthew Hedberg has maintained an Outperform rating on Trade Desk (NASDAQ:TTD) but has reduced the price target from $100 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:27 pm

SLVM

RBC Capital analyst Paul Quinn has maintained a 'Sector Perform' rating on Sylvamo (NYSE:SLVM) and increased the price target from $44 to $45.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:26 pm

PLRX

RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) but reduced the price target from $54 to $53.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:24 pm

NBIX

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Neurocrine Biosciences (NASDAQ:NBIX) but has lowered the price target from $128 to $121.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:20 pm

MODN

RBC Capital analyst Rishi Jaluria maintains a Sector Perform rating on Model N (NYSE:MODN) and reduces the price target from $35 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:18 pm

NTLA

RBC Capital analyst Luca Issi has maintained an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) but has reduced the price target from $80 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 7:13 pm